153 related articles for article (PubMed ID: 15742383)
21. An array of target-specific screening strains for antibacterial discovery.
DeVito JA; Mills JA; Liu VG; Agarwal A; Sizemore CF; Yao Z; Stoughton DM; Cappiello MG; Barbosa MD; Foster LA; Pompliano DL
Nat Biotechnol; 2002 May; 20(5):478-83. PubMed ID: 11981561
[TBL] [Abstract][Full Text] [Related]
22. Screening the receptorome: an efficient approach for drug discovery and target validation.
Strachan RT; Ferrara G; Roth BL
Drug Discov Today; 2006 Aug; 11(15-16):708-16. PubMed ID: 16846798
[TBL] [Abstract][Full Text] [Related]
23. New approaches for male fertility control: HE6 as an example of a putative target.
Gottwald U; Davies B; Fritsch M; Habenicht UF
Mol Cell Endocrinol; 2006 May; 250(1-2):49-57. PubMed ID: 16442214
[TBL] [Abstract][Full Text] [Related]
24. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
25. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
26. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.
Showalter HD; Denny WA
Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S3-17. PubMed ID: 18762151
[TBL] [Abstract][Full Text] [Related]
27. Fragments, network biology and designing multiple ligands.
Morphy R; Rankovic Z
Drug Discov Today; 2007 Feb; 12(3-4):156-60. PubMed ID: 17275736
[TBL] [Abstract][Full Text] [Related]
28. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
29. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
[TBL] [Abstract][Full Text] [Related]
30. siRNAs in drug discovery: target validation and beyond.
Natt F
Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
[TBL] [Abstract][Full Text] [Related]
31. Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens.
Perrimon N; Friedman A; Mathey-Prevot B; Eggert US
Drug Discov Today; 2007 Jan; 12(1-2):28-33. PubMed ID: 17198970
[TBL] [Abstract][Full Text] [Related]
32. Targeting disease, not disease targets: Innovative approaches in tackling neurodegenerative disorders.
Griffioen G
IDrugs; 2007 Apr; 10(4):259-63. PubMed ID: 17390249
[TBL] [Abstract][Full Text] [Related]
33. Aptamers as tools for target validation.
Blank M; Blind M
Curr Opin Chem Biol; 2005 Aug; 9(4):336-42. PubMed ID: 16006181
[TBL] [Abstract][Full Text] [Related]
34. Chemical proteomics-based drug design: target and antitarget fishing with a catechol-rhodanine privileged scaffold for NAD(P)(H) binding proteins.
Ge X; Wakim B; Sem DS
J Med Chem; 2008 Aug; 51(15):4571-80. PubMed ID: 18616236
[TBL] [Abstract][Full Text] [Related]
35. Focus issue: drug discovery.
Gough NR
Sci STKE; 2005 Aug; 2005(295):eg7. PubMed ID: 16077084
[TBL] [Abstract][Full Text] [Related]
36. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
Hu S; Yen Y; Ann D; Wong DT
Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
[TBL] [Abstract][Full Text] [Related]
37. Screening for transient biological interactions as applied to albumin ligands: a new concept for drug discovery.
Ohlson S; Shoravi S; Fex T; Isaksson R
Anal Biochem; 2006 Dec; 359(1):120-3. PubMed ID: 17052679
[TBL] [Abstract][Full Text] [Related]
38. Seeing small molecules in action with bioorthogonal chemistry.
Raghavan AS; Hang HC
Drug Discov Today; 2009 Feb; 14(3-4):178-84. PubMed ID: 18973827
[TBL] [Abstract][Full Text] [Related]
39. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system.
Bowman AL; Lerner MG; Carlson HA
J Am Chem Soc; 2007 Mar; 129(12):3634-40. PubMed ID: 17335207
[TBL] [Abstract][Full Text] [Related]
40. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-VeitÃa M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]